SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Amex: HTI - News), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Nasdaq has approved the Company's application for listing on the Nasdaq Global Market. Halozyme anticipates that its common stock will begin trading under the ticker symbol "HALO" on May 10, 2007. Halozyme's stock will continue to trade on the American Stock Exchange under the symbol "HTI.R" until the effective date.
